Related Experiment Video
Updated: Jun 16, 2026

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model
Published on: November 4, 2025
Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study
Lieven Lagae1, Helène Verhelst, Berten Ceulemans
1University Hospitals KULeuven, Department of Pediatric Neurology, Herestraat 49, 3000 Leuven, Belgium. lieven.lagae@uzleuven.be
Insights
Infantile spasms treatment varies, but outcomes remain poor. Even with early spasm control, developmental delays are common, especially in symptomatic cases.
Area of Science:
- Pediatric Neurology
- Developmental Neuroscience
Background:
- Infantile spasms (IS) with hypsarrhythmia are a severe epilepsy syndrome in infants.
- Treatment strategies and long-term outcomes for IS require further investigation.
Purpose of the Study:
- To analyze initial treatment strategies for infantile spasms.
- To evaluate the long-term neurodevelopmental outcomes in infants with IS.
Main Methods:
- Systematic retrospective review of 51 infants diagnosed with infantile spasms and hypsarrhythmia.
- Analysis of treatment protocols, time to spasm cessation, and long-term follow-up data (>2 years).
Main Results:
- Vigabatrin was the most common first-line treatment; hormonal therapy, topiramate, and valproate were used as second-line options.
- Time to spasm cessation was faster in cryptogenic IS (13 days) than symptomatic IS (66 days), irrespective of treatment.
- Long-term follow-up revealed epilepsy in 60% and psychomotor delay in 75% of infants; outcomes were better in cryptogenic cases but still showed significant developmental delay.
Conclusions:
- Underlying brain dysfunction significantly impacts long-term outcomes in symptomatic infantile spasms.
- Even in cryptogenic infantile spasms, early spasm control does not prevent later developmental delays, indicating IS itself can contribute to neurodevelopmental deficits.
Abstract:
We systematically reviewed the files of 51 infants presenting with infantile spasms and hypsarrhythmia in order to study the initial treatment strategies and the long term outcome. 80% of the infants were classified as symptomatic. In the nine participating centres, different treatment protocols were used, but the large majority of the children received vigabatrin as first line treatment. Second line options included hormonal treatment, topiramate and valproate. The time to reach cessation of infantile spasms was significantly shorter in the cryptogenic group than in the symptomatic group (50% at 13 days versus 66 days respectively) and was irrespective of the treatment used. The late follow up data (>2 years) showed that 60% of the children had epilepsy and that 75% of the children had a delay in their psychomotor development. Again, outcome in the cryptogenic group was better than in the symptomatic group, but also in the cryptogenic group, 50% of the children had a clear developmental delay, even if spasms were controlled early in the course of the disease. Our retrospective study illustrates that not only the underlying brain dysfunction is the major determinant for later outcome in infantile spasms (symptomatic group) but also even a short period of infantile spasms can be responsible for later developmental delay (cryptogenic group).
Related Concept Videos
Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe and...
Psychosis: Goals of Pharmacotherapy
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological and Sociocultural Causes of Schizophrenia
Sex Linked Disorders
Clinical Trials: Overview